GRAVINA, GIOVANNI LUCA
 Distribuzione geografica
Continente #
NA - Nord America 2.631
EU - Europa 520
AS - Asia 220
AF - Africa 12
SA - Sud America 5
Totale 3.388
Nazione #
US - Stati Uniti d'America 2.614
IT - Italia 177
SE - Svezia 125
IN - India 109
CN - Cina 69
FI - Finlandia 44
UA - Ucraina 41
SG - Singapore 37
IE - Irlanda 26
GB - Regno Unito 22
RO - Romania 20
DE - Germania 16
CA - Canada 13
TG - Togo 10
PL - Polonia 9
BG - Bulgaria 7
RU - Federazione Russa 7
CH - Svizzera 6
FR - Francia 5
AR - Argentina 4
MX - Messico 4
BE - Belgio 3
NL - Olanda 3
CZ - Repubblica Ceca 2
DK - Danimarca 2
HK - Hong Kong 2
ZA - Sudafrica 2
AT - Austria 1
CL - Cile 1
EE - Estonia 1
ES - Italia 1
IQ - Iraq 1
KR - Corea 1
LT - Lituania 1
RS - Serbia 1
TR - Turchia 1
Totale 3.388
Città #
Fairfield 500
Woodbridge 226
Ashburn 215
Seattle 199
Houston 176
Cambridge 170
Wilmington 144
Chandler 136
Ann Arbor 83
Dearborn 80
Princeton 71
Rome 61
Plano 54
Lawrence 52
San Paolo di Civitate 41
Boston 38
Beijing 28
Fremont 27
Dublin 26
Millbury 25
San Diego 21
New York 17
Des Moines 15
Norwalk 14
Andover 10
Lomé 10
Phoenix 10
Milan 9
Helsinki 8
Jacksonville 8
San Severo 7
Singapore 7
Sofia 7
Southend 6
Toronto 6
Kunming 5
Menlo Park 5
Ottawa 5
Boardman 4
Federal 4
Hefei 4
Jinan 4
Nanjing 4
Siedlce 4
Villa Park 4
Bern 3
Guangzhou 3
Laurel 3
London 3
Los Angeles 3
L’Aquila 3
Moscow 3
Pescara 3
Pune 3
Stafford 3
Tarnów 3
Zurich 3
Brussels 2
Changsha 2
Chengdu 2
Dallas 2
Flushing 2
Fort Worth 2
Fuzhou 2
Hebei 2
Marino 2
Mexico City 2
Mielec 2
Muizenberg 2
Nepi 2
Redmond 2
San Benedetto Ullano 2
San Mateo 2
Shanghai 2
Sheffield 2
Sorrento 2
Termoli 2
Acireale 1
Arnsberg 1
Ashford 1
Azcapotzalco 1
Bassano Romano 1
Belgrade 1
Brescia 1
Buffalo 1
Chicago 1
Chiswick 1
Chongqing 1
Clifton 1
Columbus 1
Council Bluffs 1
Falls Church 1
Glasgow 1
Gorham 1
Grafing 1
Grossheirath 1
Gunzenhausen 1
Innsbruck 1
Istanbul 1
Jiaxing 1
Totale 2.649
Nome #
Premature Ejaculation Results in Female Sexual Distress: Standardization and Validation of a New Diagnostic Tool for Sexual Distress 138
Advances in prostate cancer research and treatment. 101
Attachment styles and sexual dysfunctions: a case-control study of female and male sexuality 98
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells 93
Ontogenetic profile of the expression of thyroid hormone receptors in rat and human corpora cavernosa of the penis. 85
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results 81
Effects of EGFR Tyrosine Kinase Inhibitor Erlotinib in Prostate Cancer Cells In Vitro 81
The ENDOTRIAL Study: A spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction 78
Alexithymia and vaginismus: a preliminary correlation perspective 75
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population 74
XPO1/CRM1-SELECTIVE INHIBITORS OF NUCLEAR EXPORT (SINE) REDUCE TUMOR SPREADING AND IMPROVE OVERALL SURVIVAL IN PRECLINICAL MODELS OF PROSTATE CANCER (PCa). 74
A feasibility study of percutaneous radiofrequency ablation followed by radiotherapy in the management of painful osteolytic bone metastases 74
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models 73
Italian Validation of Homophobia Scale (HS) 72
5-Azacitidine Restores and Amplifies the Bicalutamide Response on Preclinical Models of Androgen Receptor Expressing or Deficient Prostate Tumors 72
The small molecule ephrin receptor inhibitor, GLPG1790, Reduces renewal capabilities of cancer stem cells, showing anti-tumour efficacy on preclinical glioblastoma models 68
Is Testosterone a Food for the Brain? 67
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation 67
New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors 65
Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. 65
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma 64
Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer 63
The sexual attraction toward disabilities: a preliminary internet-based study. 62
NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance 62
Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know? 60
Integrating psychotherapy and pharmacotherapy in the treatment of premature ejaculation 60
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 60
null 59
SIAMS survey on sexological screening during the assisted reproductive technologies in Italy 59
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma 57
Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells 57
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models 56
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay 56
The TORC1/TORC2 inhibitor, palomid 529 (P529), reduces tumor growth and sensitizes to chemotherapy and radiotherapy aggressive hormone refractory prostate cancer cells both in vitro and in vivo 55
Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer 55
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR ser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy 54
HORMONAL THERAPY PROMOTES HORMONE-RESISTANT PHENOTYPE BY INCREASING DNMT ACTIVITY AND EXPRESSION IN PROSTATE CANCER MODELS 53
Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis 52
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples 52
Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer 52
The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study 51
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer 50
Intravesical instillations with polydeoxyribonucleotides reduce symptoms of radiation-induced cystitis in patients treated with radiotherapy for pelvic cancer: a pilot study 49
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer 49
ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma 49
Moderate hypofractionation in patients with low-risk prostate cancer: long-term outcomes 47
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models 45
Strategies for Imaging Androgen Receptor Signaling Pathway in Prostate Cancer: Implications for Hormonal Manipulation and Radiation Treatment 44
One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients 42
Clinical challenges in the management of premature ejaculation 37
Oral platelet gel supernatant plus supportive medical treatment versus supportive medical treatment in the management of radiation-induced oral mucositis: a matched explorative active control trial by propensity analysis 36
The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo 34
Abscopal effect on bone metastases from solid tumors: a systematic review and retrospective analysis of challenge within a challenge 31
THE RISK OF HYPOGONADISM IN CANCER SURVIVORS WITH STAGE-I TESTICULAR SEMINOMA TREATED BY ADJUVANT RADIOTHERAPY 30
AZACITIDINE TREATMENT SENSITIZES AGAINST BICALUTAMIDE AND RADIOTHERAPY IN ANDROGEN INDEPENDENT PROSTATE CANCER CELLS 27
THE VALUE OF BIOPSY LATERALITY IN ASSOCIATION WITH PSA AND GLEASON SCORE FOR THE IDENTIFICATION OF SUBJECTS AT HIGH RISK OF RECURRENCE IN PROSTATE CANCER 24
Gossypol Induces Apoptosis and Synergize With Radiotherapy and Temozolomide in Glioblastoma Cells 22
The brain penetrating pan EPH receptor antagonist, UNIPR1331, shows potent antiangiogenic and anti-invasive effects in glioblastoma preclinical models 22
MS−275 (Entinostat) promotes radio-sensitivity in PAX3-FOXO1 rhabdomyosarcoma cells 22
Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case report. 21
Voluntary interruption of pregnancy worsens the Female sexual well-being 14
Post-traumatic stress disorder, coping strategies and type 2 diabetes: psychometric assessment after L’Aquila earthquake 7
Totale 3.502
Categoria #
all - tutte 8.500
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.500


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019386 0 0 0 0 0 0 0 0 0 0 212 174
2019/20201.020 133 37 22 35 105 163 154 124 105 67 41 34
2020/2021305 45 40 13 17 4 38 7 22 41 43 29 6
2021/2022599 7 43 61 25 72 7 16 78 50 45 89 106
2022/2023607 123 133 26 56 55 65 10 40 68 2 22 7
2023/2024279 49 44 14 20 41 33 13 18 3 42 2 0
Totale 3.502